Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.

导出 OA

翻译打印收藏纠错

作者： Corneel,Coens ^[1] ; Stefan,Suciu ^[2] ; Vanna,Chiarion-Sileni ^[3] ; Jean-Jacques,Grob ^[4] ; Reinhard,Dummer ^[5] ; Jedd D,Wolchok ^[6] ; Henrik,Schmidt ^[7] ; Omid,Hamid ^[8] ; Caroline,Robert ^[9] ; Paolo A,Ascierto ^[10] ; Jon M,Richards ^[11] ; Celeste,Lebbé ^[12] ; Virginia,Ferraresi ^[13] ; Michael,Smylie ^[14] ; Jeffrey S,Weber ^[15] ; Michele,Maio ^[16] ; Andrew,Bottomley ^[2] ; Srividya,Kotapati ^[17] ; Veerle,de Pril ^[18] ; Alessandro,Testori ^[19] ; Alexander M M,Eggermont ^[9]

作者单位： EORTC Headquarters, Brussels, Belgium. Electronic address: corneel.coens@eortc.be. ^[1] EORTC Headquarters, Brussels, Belgium. ^[2] IOV-IRCCS, Melanoma Oncology Unit, Padova, Italy. ^[3] Hôpital de la Timone, Marseille, France. ^[4] University of Zürich Hospital, Zürich, Switzerland. ^[5] Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[6] Aarhus University Hospital, Aarhus, Denmark. ^[7] The Angeles Clinic and Research Institute, Los Angeles, CA, USA. ^[8] Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. ^[9] Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy. ^[10] Oncology Specialists S C, Park Ridge, IL, USA. ^[11] Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Paris. ^[12] Istituti Fisioterapici Ospitalieri, Rome, Italy. ^[13] Cross Cancer Institute, Edmonton, AB, Canada. ^[14] H Lee Moffitt Cancer Center, Tampa, FL, USA. ^[15] University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. ^[16] Bristol-Myers Squibb, Wallingford, CT, USA. ^[17] Bristol-Myers Squibb, Braine-l'Alleud, Belgium. ^[18] European Institute of Oncology, Milan, Italy. ^[19]